Minerva Neurosciences, Inc (NERV): Price and Financial Metrics
NERV Price/Volume Stats
| Current price | $2.51 | 52-week high | $13.49 |
| Prev. close | $2.50 | 52-week low | $2.26 |
| Day low | $2.50 | Volume | 6,163 |
| Day high | $2.53 | Avg. volume | 106,055 |
| 50-day MA | $4.09 | Dividend yield | N/A |
| 200-day MA | $6.59 | Market Cap | 17.55M |
NERV Stock Price Chart Interactive Chart >
Minerva Neurosciences, Inc (NERV) Company Bio
Minerva Neurosciences, Inc. focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company was founded in 2007 and is based in Waltham, Massachusetts.
Latest NERV News From Around the Web
Below are the latest news stories about MINERVA NEUROSCIENCES INC that investors may wish to consider to help them evaluate NERV as an investment opportunity.
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business UpdatesBURLINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the third quarter ended September 30, 2023. The Company continues to work with the U.S. Food and Drug Administration (FDA) during its review of its New Drug Application (NDA) for roluperidone for the treatment of negati |
12 Best Performing Biotech Stocks in 2023In this piece, we will take a look at the 12 best performing biotechnology stocks in 2023. If you want to skip our introduction to the biotechnology industry and some top players, then check out 5 Best Performing Biotech Stocks in 2023. Biotechnology is one of the hottest industries these days and one that has […] |
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business UpdatesBURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the second quarter ended June 30, 2023. “In the second quarter, we completed an equity financing of $20.0 million, further strengthening our cash position. This investment from Boehringer Ingelheim and Federated Hermes |
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to MarketBURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it has agreed to sell an aggregate of 1,425,000 shares of its common stock at a purchase price of $10 per share and pre-funded warrants to purchase an aggregate of 575,575 shares of its common stock at a purchase price of $9.99 per pre-funded warrant, to B |
Here's Why Minerva Neurosciences (NERV) Is a Great 'Buy the Bottom' Stock NowMinerva Neurosciences (NERV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. |
NERV Price Returns
| 1-mo | -7.04% |
| 3-mo | -66.67% |
| 6-mo | -54.28% |
| 1-year | -12.54% |
| 3-year | -86.98% |
| 5-year | -95.54% |
| YTD | -59.19% |
| 2023 | 286.79% |
| 2022 | -75.19% |
| 2021 | -65.77% |
| 2020 | -67.09% |
| 2019 | 5.49% |
Loading social stream, please wait...